Subtypes and beyond: naming and describing diffuse large B-cell lymphoma in an era of many treatments
Diffuse large B-cell lymphoma (DLBCL) comprises biologically diverse tumors. Cell-of-origin, dark-zone and genetic subtypes provide a valuable shared language that increasingly informs clinical trials and treatment selection. Independently developed genetic classifiers identify remarkably similar subtypes but disagree at their boundaries, reflecting biological overlap, differences in discovery cohorts and variation in mutation detection and interpretation. Moreover, existing categories compress biological complexity and capture only part of the information relevant to treatment response. Recent advances reveal complementary dimensions of DLBCL biology, including the non-coding regulatory genome, proteomic and post-translational features, the tumor microenvironment, malignant-cell state, clonal evolution and spatial organization. These dimensions provide information partly independent of existing classifications, as illustrated by a MYC-active proteomic group associated with early R-CHOP failure across genetic subtypes, an oligomannose-defined group within GCB DLBCL, and microenvironment archetypes associated with different outcomes after immunochemotherapy and CAR-T. As therapeutic options diversify, these additional dimensions become increasingly relevant, but do not by themselves warrant new subtypes. Instead, their clinical relevance depends on the treatment under consideration. We propose three complementary levels of characterization: naming tumors using robust categories suitable for routine diagnostic use; describing individual tumors through standardized, multidimensional molecular and clinical data; and ultimately forecasting treatment-specific outcomes. Much of this requires agreement rather than discovery: harmonized mutation calling, retention of underlying molecular data and pooling of trial datasets linked to treatment and outcome. As the repertoire of effective but increasingly costly therapies expands, molecular characterization must keep pace to ensure these treatments are deployed where they offer greatest benefit.
Authors
- Daniel James Hodson (ORCID: https://orcid.org/0000-0001-6225-2033)
Publication Details
- Journal
- Apollo
- Published
- 2026-11-21
- DOI
- https://doi.org/10.17863/cam.137004
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00